Outcomes after Percutaneous Angioplasty of Arteriovenous Fistulas and Grafts in African American Patients

Abstract

French

Purpose

Arteriovenous fistulas and grafts, necessary for hemodialysis, may develop stenoses due to neointimal hyperplasia, which often require percutaneous transluminal angioplasty. Patient and lesion characteristics were evaluated prior to angioplasty and were correlated with 1- and 6-month outcomes.

Materials and Methods

This was an observational study of African American hemodialysis patients who presented for angioplasty of a dysfunctional fistula or graft. Clinical outcomes were ascertained from dialysis facilities 1 month and 6 months after angioplasty. One-month clinical success was defined as dialyzer blood flows of 450 mL/min without complications or interval shunt thrombosis, interventions, or loss of access, which was rarely achieved at 6 months. Logistic regression models were used to evaluate associations of clinical variables with outcomes.

Results

There were 150 stenoses treated during 99 procedures performed on 82 patients. The clinical success rate at one month was 67% with no complications as a result of the percutaneous transluminal angioplasty. Success at 1 month was positively associated with use of aspirin (P = .005) and with referral for high venous pressures (P = .004). Six-month data were available for 81 procedures, with 45.7% requiring repeat angioplasty and 12.3% suffering major complications (thrombectomy, revision surgery, or access abandonment). Major complications were seen predominantly in patients who were not receiving aspirin.

Conclusions

Aspirin use and high venous pressure were associated with 1-month clinical success and fewer major complications at 6 months. Future work should investigate biologic mechanisms of action of aspirin and long-term effects of use to maintain vascular access.

Keywords

Hemodialysis Arteriovenous fistula Arteriovenous graft Percutaneous angioplasty

Get full access to this article

View all access options for this article.

References

United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. National Institutes of Health, National institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2017.

Riella

M.C.

Roy-Chaudhury

Vascular access in haemodialysis: strengthening the Achilles' heel

Nat Rev Nephrol 9 2013 348–357 Riella MC, Roy-Chaudhury P. Vascular access in haemodialysis: strengthening the Achilles’ heel. Nat Rev Nephrol 2013;9:348-357.

Maeda

Furukawa

Yamasaki

Murata

Percutaneous transluminal angioplasty for Brescia-Cimino hemodialysis fistula dysfunction: technical success rate, patency rate and factors that influence the results

Eur J Radiol 54 2005 426–430 Maeda K, Furukawa A, Yamasaki M, Murata K. Percutaneous transluminal angioplasty for Brescia-Cimino hemodialysis fistula dysfunction: technical success rate, patency rate and factors that influence the results. Eur J Radiol 2005;54:426-430.

Neuen

Gunnarsson

Webster

A.C.

Baer

R.A.

Golledge

Mantha

Predictors of patency after balloon angioplasty in hemodialysis fistulas: a systematic review

J Vasc Interv Radiol 25 2014 917–924 Neuen B, Gunnarsson R, Webster AC, Baer RA, Golledge J, Mantha M. Predictors of patency after balloon angioplasty in hemodialysis fistulas: a systematic review. J Vasc Interv Radiol 2014;25:917-924.

Clark

T.W.I.

Hirsch

D.A.

Jindahl

K.J.

Veugelers

P.J.

LeBlanc

Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas

J Vasc Inter Radiology 13 2002 51–59 Clark TWI, Hirsch DA, Jindahl KJ, Veugelers PJ, LeBlanc J. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas. J Vasc Inter Radiology 2002;13:51-59.

Rajan

D.K.

Bunston

Misra

Pinto

Lok

Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty—are there clinical predictors of patency?

Radiology 232 2004 508–515 Rajan DK, Bunston S, Misra S, Pinto R, Lok C. Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty-are there clinical predictors of patency? Radiology 2004;232:508-515.

Lip

G.Y.

Niewlaat

Pister

Lane

D.A.

Crijns

H.J.

Refining clinical risk stratification using a novel risk-factor based approach in the euro heart survey on atrial fibrillation

Chest 137 2010 263–272 Lip GY, Niewlaat R, Pister R, Lane DA, Crijns HJ. Refining clinical risk stratification using a novel risk-factor based approach in the euro heart survey on atrial fibrillation. Chest 2010;137:263-272.

Bountouris

Kritikou

Degermetzoglou

Avgerinos

K.I.

A review of percutaneous transluminal angioplasty in hemodialysis fistula

Int J Vas Med 2018 2018 1420136 Bountouris I, Kritikou G, Degermetzoglou N, Avgerinos KI. A review of percutaneous transluminal angioplasty in hemodialysis fistula. Int J Vas Med 2018;2018:1420136.

Dariushnia

S.R.

Walker

Siberzweig

J.E.

Quality improvement guidelines for percutaneous image-guided management of the thrombosed or dysfunctional dialysis circuit

J Vasc Interv Radiol 27 2016 1518–1530 Dariushnia SR, Walker G, Siberzweig JE, et al. Quality improvement guidelines for percutaneous image-guided management of the thrombosed or dysfunctional dialysis circuit. J Vasc Interv Radiol 2016;27:1518-1530.

10.

C.C.

Wen

S.C.

Yang

C.W.

Plasma ADMA predicts restenosis of arteriovenous fistula

J Am Soc Nephrol 20 2009 213–222 Wu CC, Wen SC, Yang CW, et al. Plasma ADMA predicts restenosis of arteriovenous fistula. J Am Soc Nephrol 2009;20:213-222.

11.

Aktas

Bozkurt

Aktas

Kibras

Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting post-procedural fistula patency

Diagn Interv Radiol 21 2015 160–166 Aktas A, Bozkurt A, Aktas B, Kibras I. Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting post-procedural fistula patency. Diagn Interv Radiol 2015;21:160-166.

12.

Chang

H.H.

Chang

Y.K.

C.W.

Statins improve long term patency of arteriovenous fistula for hemodialysis

Sci Rep 6 2016 22197 Chang HH, Chang YK, Lu CW, et al. Statins improve long term patency of arteriovenous fistula for hemodialysis. Sci Rep 2016;6:22197.

13.

Tanner

N.C.

Da Silva

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts

Cochrane Database Syst Rev 2015 CD002786 Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 2015:CD002786.

14.

Saran

Dykstra

D.M.

Wolfe

R.A.

Gillespie

Held

P.J.

Young

E.W.

Association between vascular access failure and the use of specific drugs: the dialysis outcomes and practice patterns study (DOPPS)

Am J Kidney Dis 40 2002 1255–1263 Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2002;40:1255-1263.

15.

Dember

L.M.

Beck

G.J.

Allon

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial

JAMA 299 2008 2164–2171 Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299:2164-2171.

16.

Dixon

B.S.

Beck

G.J.

Vazquez

M.A.

Effect of dipyridamole plus aspirin on hemodialysis graft patency

N Engl J Med 360 2009 2191–2201 Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009;360:2191-2201.

17.

Liao

J.K.

Laufs

Pleiotrophic effects of statins

Annu Rev Pharmacol Toxicol 45 2005 89–118 Liao JK, Laufs U. Pleiotrophic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.

18.

Janardhanan

Yang

Vohra

Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model

Kidney Int 84 2013 338–352 Janardhanan R, Yang B, Vohra P, et al. Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int 2013;84:338-352.

19.

Liu

P.Y.

Liu

L.J.

Lin

C.Y.

Chen

J.H.

Liao

J.K.

Evidence for statin pleiotropy in humans

Circulation 119 2008 1–8 Liu PY, Liu LJ, Lin CY, Chen JH, Liao JK. Evidence for statin pleiotropy in humans. Circulation 2008;119:1-8.

20.

Righetti

Ferraro

Serbelloni

Milaniu

Tommasi

Some old drugs improve late primary patency rates of native arteriovenous fistulas in hemodialysis patients

Ann Vasc Surg 23 2009 491–497 Righetti M, Ferraro G, Serbelloni P, Milaniu S, Tommasi A. Some old drugs improve late primary patency rates of native arteriovenous fistulas in hemodialysis patients. Ann Vasc Surg 23 2009:491-497.

21.

Martinez

Duque

J.C.

Escobar

L.A.

Drug specific effects of three different statins primary arteriovenous fistulas in hemodialysis patients

J Vasc Access 17 2016 471–476 Martinez L, Duque JC, Escobar LA, et al. Drug specific effects of three different statins primary arteriovenous fistulas in hemodialysis patients. J Vasc Access 2016;17:471-476.

22.

Birch

Fillaus

Florescu

M.C.

The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses

Hemodial Int 17 2012 586–593 Birch N, Fillaus J, Florescu MC. The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses. Hemodial Int 2012;17:586-593.

23.

Kim

S.M.

H.K.

Noh

Factors affecting patency following successful percutaneous intervention for dysfunctional hemodialysis vascular access

Ann Vasc Surg 47 2017 54–61 Kim SM, Ko HK, Noh M, et al. Factors affecting patency following successful percutaneous intervention for dysfunctional hemodialysis vascular access. Ann Vasc Surg 2017;47:54-61.

24.

Vissinger

Husted

S.E.

Kristensen

S.D.

Nielsen

H.K.

Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid

Angiology 44 1993 633–638 Vissinger H, Husted SE, Kristensen SD, Nielsen HK. Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid. Angiology 1993;44:633-638.

25.

Hart

C.E.

Clowes

A.W.

Platelet-derived growth factor and arterial response to injury

Circulation 95 1997 555–556 Hart CE, Clowes AW. Platelet-derived growth factor and arterial response to injury. Circulation 1997;95:555-556.

26.

Grosser

Schroder

Aspirin protects endothelial cells from oxidant damage via the nitric oxide-CGMP pathway

Arterioscler Thromb Vasc Biol 23 2003 1345–1351 Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-CGMP pathway. Arterioscler Thromb Vasc Biol 2003;23:1345-1351.

27.

Wink

D.A.

Miranda

K.M.

Espey

M.G.

Mechanisms of the antioxidant effects of nitric oxide

Antioxid Redox Signal 3 2001 203–213 Wink DA, Miranda KM, Espey MG, et al. Mechanisms of the antioxidant effects of nitric oxide. Antioxid Redox Signal 2001;3:203-213.

28.

Fan

P.Y.

Lee

C.C.

Liu

S.H.

Preventing arteriovenous stunt failure in hemodialysis patients: a population-based cohort study

J Thromb Haemost 16 2018 1–11 Fan PY, Lee CC, Liu SH, et al. Preventing arteriovenous stunt failure in hemodialysis patients: a population-based cohort study. J Thromb Haemost 2018;16:1-11.

29.

Locham

Beaulieu

R.J.

Dakour-Aridi

Neji

Malas

M.B.

Role of antiplatelet therapy in the durability of hemodialysis access

J Nephrology 31 2018 603–611 Locham S, Beaulieu RJ, Dakour-Aridi H, Neji, B, Malas MB. Role of antiplatelet therapy in the durability of hemodialysis access. J Nephrology 2018;31:603-611.

30.

McGill

R.L.

Lacson

Sex, race and hemodialysis vascular access processes

J Vasc Access 18 2017 132–138 McGill RL, Lacson E. Sex, race and hemodialysis vascular access processes. J Vasc Access 2017;18:132-138.

31.

Ford

E.S.

Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010

J Am Coll Cardio 61 2013 2249–2252 Ford ES. Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardio 2013;61:2249-2252.

32.

Loja

M.N.

Brunson

C.S.

Racial disparities in outcomes of endovascular procedures for peripheral arterial disease: An evaluation of California hospitals. 2005-2009

Ann Vasc Surg 29 2015 950–959 Loja MN, Brunson A, Li CS, et al. Racial disparities in outcomes of endovascular procedures for peripheral arterial disease: An evaluation of California hospitals. 2005-2009. Ann Vasc Surg 2015;29:950-959.

33.

Tourdot

B.E.

Conaway

Niisuke

Edelstein

L.C.

Bray

P.F.

Holinstat

Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis

Arterioscler Thromb Vasc Biol 34 2014 2644–2650 Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol 2014;34:2644-2650.

34.

Fong

Cheng-Ching

Hussain

M.S.

Katzan

Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke

J Stroke Cerebrovasc Dis 20 2011 227–230 Fong J, Cheng-Ching E, Hussain MS, Katzan I. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2011;20:227-230.

35.

Waksman

Maya

Angiolillo

D.J.

Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: prospective, randomized, open-label, multiple-dose, crossover pilot study

Circ Cardiovasc Interv 8 2015 e002232 Waksman R, Maya J, Angiolillo DJ, et al. Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: prospective, randomized, open-label, multiple-dose, crossover pilot study. Circ Cardiovasc Interv 2105;8:e002232.